Risk factors for venous thrombosis in the black population

Summary

Risk factors for venous thrombo-embolism (VTE) in the black population are poorly characterized. Of 142 black cases tested a genetic cause was identified in only 9.1%: 4.2% had protein C deficiency, 2.8% protein S deficiency, 0.7% antithrombin deficiency and 1.4% were heterozygous for FV Leiden. We hypothesised that elevated factor VIII levels constitute a candidate risk factor for venous thrombosis in the black population. Factor VIII (FVIII:C) levels were determined in 100 black patients with VTE and 100 black controls in a case-control study. Of the patients 34% had a FVIII:C above 228 IU/dL (the 90^thcentile value in normal blacks) compared to 10% controls. Relative to those with FVIII:C below this value, odds ratio (OR) for risk of VTE was 4.64 (95% CI 2.02-10.85). When FVIII:C below 150 IU/dL was used as a comparator, OR was 11.1 (95% CI 4.29-29.43). There was evidence for a dose-response relationship. We propose that raised FVIII:C is a major risk factor for VTE in black subjects with prevalence and odds ratio exceeding those reported for white subjects.

Keywords

Venous thrombosis - factor VIII - black - thrombophilia - risk factors

• References

• 1 Dowling NF, Austin H, Dilley A. et al The epidemiology of venous thromboembolism in Caucasians and Afro-Americans: the GATE Study. J Thromb Haemost 2002; 1: 80-7.
• 2 Rees DC, Chapman NH, Webster MT. et al Born to clot the European burden. Br J Haematol 1999; 105 (02) 564-6.
• 3 Koster T, Blann AD, Briet E. et al Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
• 4 Kraaijenhagen RA, in’t Anker PS. et al High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
• 5 Kyrle PA, Minar E, Hirschl M. et al High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.
• 6 van der Meer FJM, Koster T, Vandenbroucke JP. et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78 (01) 631-5.
• 7 Patel RK, Messenger J, Bonner L. et al Venous thromboembolism in the black population. Br J Haematol 2002; 117 (01) 24a.
• 8 Conlan MG, Folsom AR, Finch A. et al Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70 (03) 380-5.
• 9 Miller CH, Dilley A, Richardson L. et al Population differences in von Willebrand factor levels affect the diagnosis of von Willebrands disease in African-American women. Am J Haematol 2001; 67 (02) 125-9.
• 10 Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated Factor VIII Levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731-8.
• 11 Kamphuisen PW, Eikenboom JC, Vos HL. et al Increased levels of factor VIII and fibrino-gen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
• 12 O’Donnell J, Mumford AD, Manning RA. et al Elevation of FVIII in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-13
• 13 O’Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001; 11 (04) 343-51.
• 14 Cox Gill JC, Endres-Brooks J, Bauer PJ. et al The effect of ABO blood group in the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
• 15 Mwangi J. Blood group distribution in an urban population of patient targeted blood donors. East Afr Med J 1999; 76 (11) 615-8.
• 16 Conlan MG, Folsom AR, Finch A. et al Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 1993; 70: 380-5.
• 17 Cushman M, Yanez D, Psaty BM. et al Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study: Cardiovascular Health Study Investigators. Am J Epidemiol 1996; 143: 665-76.
• 18 Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994; 269: 23367-73.
• 19 Butenas S, van’t Veer C, Mann KG. Normal thrombin generation. Blood 1999; 94: 2169-78
• 20 O’Donnell J, Mumford AD, Manning RA. et al. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 2001; 115: 687-91.
• 21 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996; 7: 761-5.
• 22 Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198-9.
• 23 Mansvelt EPG, Laffan M, McVey M. et al Analysis of the F8 gene in individuals with high plasma factor VIII:C levels and associated venous thrombosis. Thromb Haemost 1998; 80: 561-5.
• 24 Kamphuisen PW, Eikenboom JC, Rosendaal FR. et al High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 2001; 115 (01) 156-8.
• 25 Kamphuisen PW, Eikenboom JC, Vos HL. et al Two highly variable CA-repeat polymorphisms in the factor VIII gene and the risk of venous thrombosis. Blood 1998; 90: 97b